Sunday, March 19, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

RFP: Development of Novel Therapeutics for Select Pathogens

by Global Biodefense Staff
June 27, 2014
Novel Therapeutics Development for Influenza

The National Institute of Allergy and Infectious Diseases (NIAID) this week issued a funding opportunity to support basic to translational research focused on development of novel therapeutics against select antibiotic-resistant gram-negative bacteria or influenza.

Rising resistance to anti-infective agents in healthcare and community settings is an increasing contributor to morbidity, mortality and rising healthcare costs. In addition to antimicrobial stewardship, vaccinations and hospital/community hygiene measures, there is a critical need for the development of novel therapeutic approaches to treat antimicrobial-resistant infections.

The current initiative seeks to stimulate innovation in the discovery and early development of novel therapies to meet these needs. Research areas to be supported include novel approaches or strategies targeting Gram-negative bacterial pathogens such as:

  • Targeting virulence
  • Host-directed therapeutics, including immunomodulators
  • Bacteriophage-based therapies
  • Biologics, such as monoclonal antibodies and peptides
  • Bacterial transport mechanisms to facilitate uptake or prevent efflux of antibacterials
  • Novel strategies to protect antibacterials from bacterial inactivation
  • Development of biofilm inhibitors/disruptors
  • Agents directed towards novel and or unexploited targets
  • Novel classes of agents against validated targets

This initiative also supports discovery efforts or early-stage development of novel therapies for the treatment of infections caused by subtypes of influenza A. Projects must focus on development of new drug targets and/or small molecule therapeutic interventions with broad antiviral activity against multiple influenza A subtypes, including drug-resistant strains. Research areas to be supported include, but are not limited to:

  • Identification and validation of new viral or host targets for drug discovery
  • Development of small molecule-based interventions directed at viral or host targets
  • Development of host-directed compounds that modulate the immune response
  • Development of candidates with a novel mechanism of action (other than M2 channel and neuraminidase inhibition)
  • Molecular modeling, library screening, and medicinal chemistry/structural activity relationship analysis to optimize candidate compounds for oral bioavailability
  • Preclinical characterization of candidate therapeutics, including toxicity and efficacy
  • Performing reiterative design, chemical synthesis and in vitro analysis to develop a “mature” lead compound
  • Synthesis of sufficient quantities of a lead compound(s) for preclinical characterization.

Projects focused on the development of novel drug candidate inhibitors of validated viral M2 channel or neuraminidase activities with substantially enhanced potency over licensed antivirals, oral bioavailability, and broad antiviral activity against multiple influenza A subtypes, including drug-resistant strains, will be supported under this funding effort.

Further details are available under RFA-AI-14-026. Letters of intent are due by September 19, 2014.

Tags: AntimicrobialsAntiviralsImmune ResponseInfluenzaModeling-SimulationMRSARequest for Proposals

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy